These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8281618)

  • 1. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
    Houghton PJ; Cheshire PJ; Hallman JC; Gross JL; McRipley RJ; Sun JH; Behrens CH; Dexter DL; Houghton JA
    Cancer Chemother Pharmacol; 1994; 33(4):265-72. PubMed ID: 8281618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
    Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
    Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
    Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(1):45-52. PubMed ID: 7720175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.
    Nitiss JL; Zhou J; Rose A; Hsiung Y; Gale KC; Osheroff N
    Biochemistry; 1998 Mar; 37(9):3078-85. PubMed ID: 9485461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
    McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
    Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.
    Houghton PJ; Houghton JA; Myers L; Cheshire P; Howbert JJ; Grindey GB
    Cancer Chemother Pharmacol; 1989; 25(2):84-8. PubMed ID: 2598403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
    Cobb PW; Degen DR; Clark GM; Chen SF; Kuhn JG; Gross JL; Kirshenbaum MR; Sun JH; Burris HA; Von Hoff DD
    J Natl Cancer Inst; 1994 Oct; 86(19):1462-5. PubMed ID: 8089865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
    Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
    Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts.
    Houghton PJ; Cheshire PJ; Myers L; Lutz L; Toth J; Grindey GB; Houghton JA
    Anticancer Drugs; 1995 Apr; 6(2):317-23. PubMed ID: 7795279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of DMP 840 against mouse and human solid tumor models.
    LoRusso P; Demchik L; Dan M; Polin L; Gross JL; Corbett TH
    Invest New Drugs; 1995; 13(3):195-203. PubMed ID: 8729946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
    Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ
    J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of DMP 840 in pediatric patients with refractory solid tumors.
    Thompson J; Pratt CB; Stewart CF; Avery L; Bowman L; Zamboni WC; Pappo A
    Invest New Drugs; 1998; 16(1):45-9. PubMed ID: 9740543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
    Horton JK; Houghton PJ; Houghton JA
    Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
    Houghton JA; Cook RL; Lutz PJ; Houghton PJ
    Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.